{"id":"W3005499534","doi":"10.1007/s10637-020-00904-7","title":"A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Queen's University","funders":"Canadian Cancer Society Research Institute","keywords":"Tremelimumab; Durvalumab; Tolerability; Medicine; Adverse effect; Internal medicine; Cohort; Oncology; Cancer; Nivolumab; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004356688,0.0003620205,0.001086574,0.0002793716,0.0001222465,0.0000442563,0.0002380072,0.0001075832,0.0004970228],"category_scores_gemma":[0.0003377993,0.0002833287,0.0001296958,0.0008727173,0.0002112325,0.0003135981,0.00003079999,0.0002120706,0.000006901963],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000704038,"about_ca_system_score_gemma":0.006765754,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.086987,"about_ca_topic_score_gemma":0.07634543,"domain_scores_codex":[0.996745,0.0002337969,0.001158479,0.000545993,0.0008628371,0.0004539295],"domain_scores_gemma":[0.9980865,0.0001526047,0.0005843348,0.0002523634,0.0003218156,0.0006024205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1246505,0.007400609,0.5692454,0.001877604,0.006214846,0.0005582767,0.08089046,0.007562864,0.0884663,0.00073222,0.03013,0.08227094],"study_design_scores_gemma":[0.4416655,0.01718916,0.4778204,0.004374438,0.001614067,0.00002811715,0.008161098,0.001660549,0.02026544,0.0004371601,0.02448445,0.002299652],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907533,0.000574701,0.00001357764,0.005368937,0.0002845506,0.002364083,0.0004731261,0.00004004055,0.0001276892],"genre_scores_gemma":[0.9962847,0.00009006308,0.0004274702,0.002278126,0.0001897728,0.0001400101,0.0003561979,0.00004998002,0.0001836575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3170151,"threshold_uncertainty_score":0.9999619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05438185365786288,"score_gpt":0.3286903091132746,"score_spread":0.2743084554554117,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}